Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.33 USD | -0.43% | +2.16% | -10.11% |
Financials (USD)
Sales 2024 * | 695M | Sales 2025 * | 760M | Capitalization | 1.41B |
---|---|---|---|---|---|
Net income 2024 * | 58M | Net income 2025 * | 82M | EV / Sales 2024 * | 2.31 x |
Net Debt 2024 * | 196M | Net cash position 2025 * | 49.54M | EV / Sales 2025 * | 1.79 x |
P/E ratio 2024 * |
24.9
x | P/E ratio 2025 * |
15.9
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Pacira BioSciences, Inc.
1 day | -0.43% | ||
1 week | +2.16% | ||
1 month | +15.54% | ||
3 months | +2.05% | ||
6 months | +11.18% | ||
Current year | -10.11% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Charles Reinhart
DFI | Director of Finance/CFO | 63 | 11-10-31 |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 25 M€ | -2.35% | - | |
0.18% | 43 M€ | +4.17% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 30.33 | -0.43% | 717,143 |
24-05-30 | 30.46 | +4.10% | 606,715 |
24-05-29 | 29.26 | -2.63% | 583,473 |
24-05-28 | 30.05 | +1.21% | 420,042 |
24-05-24 | 29.69 | -2.08% | 309,355 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.11% | 1.41B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- PCRX Stock